NEOIMMUNETECH, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,830 KRW | +12.68% |
|
+34.07% | -9.63% |
| 04-02 | NeoImmuneTech, Inc. Announces Chief Executive Officer Changes | CI |
| 01-15 | NeoImmuneTech, Inc. Appoints Luke Oh as President | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 40.04B 0 54.95B |
|---|---|---|---|---|---|
| Net income 2022 | -60.41B - -82.9B | Net income 2023 | -53.4B - -73.29B | EV / Sales 2022 | - |
| Net cash position 2022 | 112B 0 154B | Net cash position 2023 | 65.16B 0 89.43B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-6.53
x | P/E ratio 2023 |
-3.75
x | Employees | 100 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | +12.68% | ||
| 1 week | +34.07% | ||
| Current month | +8.99% | ||
| 1 month | +8.99% | ||
| 3 months | +7.90% | ||
| 6 months | +43.08% | ||
| Current year | -9.63% |
1 week
1 378.00
2 010.00
1 month
1 299.002 010.00
Current year
1 299.002 130.00
1 year
1 180.003 290.00
3 years
1 180.0013 650.00
5 years
1 180.0017 450.00
10 years
1 180.0017 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Se-Hwan Yang
FOU | Founder | 54 | 13-12-31 |
Tae-Woo Kim
DFI | Director of Finance/CFO | 44 | 18-04-30 |
Dana Wyche
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Se-Hwan Yang
FOU | Founder | 54 | 13-12-31 |
Soo-Hyoung Kang
BRD | Director/Board Member | - | - |
Jung-Won Woo
BRD | Director/Board Member | 64 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 1,830 | +12.68% | 8,898,046 |
| 24-04-29 | 1,624 | +4.84% | 761,458 |
| 24-04-26 | 1,549 | -6.18% | 2,205,824 |
| 24-04-25 | 1,651 | +17.93% | 10,462,980 |
| 24-04-24 | 1,400 | +0.79% | 166,134 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
NeoImmuneTech, Inc. is a clinical-stage T cell-focused biopharmaceutical company. The Company is engaged in the discovery and development of immuno-therapeutics. Its lead asset includes NT-I7 (efineptakin alfa), which is a T Cell Amplifier. NT-I7 is a human IL-7 (Interleukin-7) fusion protein that overcomes the limitations of endogenous IL-7. The IL-7 domain promotes T cell development, which plays a role in the immune response. The N-terminus of the IL-7 domain overcomes its structural instability and enables mass production of NT-I7. NT-I7 is a clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications. It is conducting multiple clinical trials of NT-I7 in multiple indications both as a monotherapy and in combination with other therapeutics, such as checkpoint inhibitors and other. Its products include NIT-106, NIT-109, NIT-110, NIT-119, NIT-120, NIT-104, NIT-107, NIT-112, NIT-105, NIT-108, NIT-113, NIT-114, NIT-115, NIT-116 and NIT-A01.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -9.63% | 26.15M | |
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +2.13% | 22.25B | |
| -14.77% | 21.68B | |
| -8.79% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
- Stock Market
- Equities
- A950220 Stock
